News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Growth hormone could be filed without further trials, says O... Drug could be filed after "outlier" analysis.
News OPKO weekly growth hormone jab fails in phase 3 US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
News England close to eliminating hep C thanks to treatment drive England is on track to be one of the first countries in the world to eliminate hepatitis C, thanks to a national diagnosis and treatment programme.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
